Dr.ย Amit Kumarย Tyagi
MD, DM (Medical Oncology)
Medical Oncologist
corporate_fareRajiv Gandhi Cancer Institute & Research Centre, New Delhi
Amit Kumar Tyagi
MD, DM (Medical Oncology)
Dr. Amit Kumar Tyagi is a Medical Oncologist at Rajiv Gandhi Cancer Institute & Research Centre (RGCIRC), New Delhi โ one of India's premier dedicated cancer hospitals. He holds advanced postgraduate qualifications (MD, DM) with training at AIIMS and RGCI, and focuses his practice on head and neck cancers, lung cancer, and gastrointestinal malignancies.
With over 15 years of experience in medical oncology, Dr. Tyagi practises within RGCIRC's organ-specific, multidisciplinary oncology framework where medical, surgical, and radiation oncology teams collaborate on diagnosis and treatment planning. His clinical work spans chemotherapy, targeted therapy, immunotherapy, and palliative care protocols aligned with internationally approved guidelines. RGCIRC's advanced infrastructure โ including molecular diagnostics, PET-CT imaging, robotic surgery, and precision radiotherapy โ gives Dr. Tyagi's patients access to the full spectrum of modern cancer care under one roof.
RGCIRC offers dedicated support for international patients including visa assistance, travel guidance, and online second-opinion services within three working days. CancerFax coordinates all logistics for overseas patients consulting Dr. Tyagi.
Why Choose Dr. Amit Kumar Tyagi?
Dr. Tyagi brings 15+ years of specialised medical oncology expertise to three of the most prevalent solid tumour types โ head and neck, lung, and gastrointestinal โ at one of India's most advanced dedicated cancer centres.
Areas of Specialization
Solid tumour medical oncology โ head & neck, thoracic, and gastrointestinal
Head & Neck Cancers
Medical oncology management of oral cavity, oropharyngeal, laryngeal, hypopharyngeal, and nasopharyngeal malignancies.
- arrow_rightPlatinum-based concurrent chemoradiation (cisplatin protocols)
- arrow_rightInduction chemotherapy (TPF โ docetaxel, cisplatin, 5-FU)
- arrow_rightAnti-EGFR targeted therapy (cetuximab) for SCCHN
- arrow_rightImmunotherapy (pembrolizumab, nivolumab) for recurrent/metastatic HNSCC
Lung Cancer
Medical oncology management of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) across all stages.
- arrow_rightEGFR-targeted therapy (osimertinib, erlotinib, gefitinib)
- arrow_rightALK/ROS1 inhibitors (alectinib, crizotinib, lorlatinib)
- arrow_rightPD-1/PD-L1 checkpoint inhibitors (pembrolizumab, atezolizumab)
- arrow_rightPlatinum doublet chemotherapy (carboplatin/paclitaxel, pemetrexed regimens)
- arrow_rightEP (etoposide + platinum) chemotherapy regimens
- arrow_rightAtezolizumab + carboplatin/etoposide for extensive-stage SCLC
- arrow_rightProphylactic cranial irradiation coordination
Gastrointestinal Cancers
Medical oncology for colorectal, gastric, oesophageal, pancreatic, and hepatobiliary malignancies.
- arrow_rightFOLFOX and FOLFIRI chemotherapy regimens for colorectal cancer
- arrow_rightAnti-VEGF (bevacizumab) and anti-EGFR (cetuximab, panitumumab) targeted therapy
- arrow_rightHER2-targeted therapy (trastuzumab) for gastric and GEJ cancers
- arrow_rightNivolumab + chemotherapy for advanced gastric cancer
- arrow_rightGemcitabine + nab-paclitaxel for pancreatic adenocarcinoma
- arrow_rightFOLFIRINOX regimen for metastatic pancreatic cancer
- arrow_rightSorafenib / lenvatinib for hepatocellular carcinoma
- arrow_rightPerioperative FLOT chemotherapy for resectable gastric/GEJ disease
Procedures & Treatments
Comprehensive medical oncology interventions across solid tumours
Chemotherapy Administration
Medical OncologySystemic cytotoxic therapy for head and neck, lung, and gastrointestinal malignancies using internationally approved protocols.
Immunotherapy
Medical OncologyPD-1/PD-L1 checkpoint inhibitor therapy for eligible patients with head and neck, lung, and GI cancers.
Targeted Therapy
Targeted TherapyMolecularly-guided oral and IV targeted agents based on tumour genomic profiling.
Molecular Diagnostic Work-Up
DiagnosisComprehensive staging and molecular profiling to guide treatment selection.
Second Opinion Consultations
Second OpinionExpert independent review of pathology, imaging, and existing treatment plans for head and neck, lung, and GI cancer cases.
Research & Publications
Academic contributions in medical oncology
For a detailed list of Dr. Tyagi's publications and research contributions, please contact CancerFax. RGCIRC actively participates in multi-centre oncology trials and national academic conferences.
Education & Training
Dr. Tyagi completed his medical oncology training through India's structured MBBS โ MD โ DM pathway, with key training at AIIMS โ India's foremost medical institution โ and Rajiv Gandhi Cancer Institute, New Delhi.
Clinical Experience
With over 15 years of experience in medical oncology, Dr. Tyagi is based at Rajiv Gandhi Cancer Institute & Research Centre โ one of India's largest standalone cancer hospitals โ providing specialist care for head and neck, lung, and gastrointestinal cancers.
Languages & International
Dr. Tyagi conducts consultations in the following languages.
International patients consulting Dr. Tyagi through CancerFax have access to professional medical interpreters โ no language barrier to expert oncology care.
CancerFax provides certified medical interpreters for Arabic, Mandarin, Russian, French, and 20+ other languages.
How CancerFax Helps You Access Dr. Amit Kumar Tyagi
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Amit Kumar Tyagi's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Amit Kumar Tyagi's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Amit Kumar Tyagi before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Amit Kumar Tyagi's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Amit Kumar Tyagi's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Amit Kumar Tyagi's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Amit Kumar Tyagi
Dr. Amit Kumar Tyagi specialises in three major solid tumour groups: head and neck cancers (oral cavity, oropharynx, larynx, and nasopharynx), lung cancer (NSCLC and SCLC), and gastrointestinal cancers (colorectal, gastric, oesophageal, and pancreatic malignancies). He provides medical oncology management including chemotherapy, targeted therapy, and immunotherapy at RGCIRC, New Delhi.
Submit your medical reports via CancerFax using the 'Send Your Reports' button on this page. Our oncology coordination team will review your case, prepare a structured summary, and schedule a consultation with Dr. Tyagi at Rajiv Gandhi Cancer Institute, New Delhi. For international patients, we also facilitate online consultations and telemedicine appointments.
Yes. RGCIRC has a dedicated international patient programme and CancerFax coordinates the full process โ including visa invitation letters, medical record preparation, interpreter services, accommodation guidance, and post-consultation follow-up. Dr. Tyagi is accessible for both in-person visits and online second opinion consultations.
For head and neck cancers, Dr. Tyagi offers concurrent chemoradiation (cisplatin-based protocols), induction chemotherapy (TPF regimen), anti-EGFR targeted therapy with cetuximab, and immunotherapy using pembrolizumab or nivolumab for recurrent or metastatic disease. Treatment selection is guided by tumour site, stage, PD-L1 expression, and multidisciplinary tumour board recommendations.
Yes. CancerFax facilitates second opinion consultations with Dr. Tyagi for lung cancer and gastrointestinal cancer cases. He reviews complete pathology reports, molecular profiling results (EGFR, ALK, MSI, HER2 status), imaging (PET-CT, CECT, MRI), and existing treatment history to provide an independent oncology assessment. RGCIRC also offers formal online second opinions within three working days.
RGCIRC is one of India's premier standalone cancer hospitals, located in New Delhi. It operates organ-specific multidisciplinary teams covering medical, surgical, and radiation oncology, and offers advanced infrastructure including molecular diagnostics, PET-CT imaging, robotic surgery, and precision radiotherapy. RGCIRC follows internationally approved, evidence-based treatment guidelines for all cancer types and supports international patients with dedicated services.
Connect with Amit Kumar Tyagi Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.